Related MeSH Hierarchy (4)
Diseases [C] » Urogenital Diseases [C12] » Female Urogenital Diseases and Pregnancy Complications » Female Urogenital Diseases » Urologic Diseases » Kidney Diseases » Renal Insufficiency » Renal Insufficiency, Chronic » Kidney Failure, Chronic
Diseases [C] » Urogenital Diseases [C12] » Male Urogenital Diseases » Urologic Diseases » Kidney Diseases » Renal Insufficiency » Renal Insufficiency, Chronic » Kidney Failure, Chronic
Diseases [C] » Urogenital Diseases [C12] » Urologic Diseases » Kidney Diseases » Renal Insufficiency » Renal Insufficiency, Chronic » Kidney Failure, Chronic
Diseases [C] » Pathological Conditions, Signs and Symptoms [C23] » Pathologic Processes » Disease Attributes » Chronic Disease » Renal Insufficiency, Chronic » Kidney Failure, Chronic
Description
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. MeSH
Hierarchy View
Subtype Terms (1)
Phase 4 Indicated Drugs (145)
23-valent pneumococcal polysaccharide vaccine (pneumovax-23)
acetylsalicylic acid (aspirin)
Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)
cytomegalovirus immune globulin intravenous (human) (cytogam)
ferric pyrophosphate citrate (Triferic)
hepatitis b vaccine (recombinant) (Recombivax)
hydroxychloroquine (plaquenil)
immune globulin (human) (Gamastan)
methoxy polyethylene glycol-epoetin beta (Mircera)
multi-valent pneumococcal conjugate vaccine
Phase 2 Indicated Drugs (85)
Other Experimental Indicated Drugs (44)
Organization Involved with Phase 4 Indications (198)
Ahvaz Jundishapur University of Medical Sciences
Albany College of Pharmacy and Health Sciences
Centre Hospitalier Departemental Vendee
Centro Medico Lic Adolfo Lopez Mate
Chinese University of Hong Kong
Chronic Liver Disease Foundation
Coney Island Hospital, Brooklyn, NY
Daewon Pharmaceutical Co., Ltd.
Dialysis Outcomes Heart Failure Aldactone Study Group
Fundacio Lluita Contra la SIDA
Fundación Renal Iñigo Alvarez De Toledo
Hamadan University of Medical Science
Hoosier Cancer Research Network
Hortense & Louis Rubin Dialysis Center
Hospital General “Dr. Miguel Silva” de Morelia
Huazhong University of Science and Technology
Institute for Health Outcomes and Process Evaluation Reseach
Instituto Mexicano del Seguro Social
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Methodist Cancer Center, Houston, Texas
Molecular Physiological Chemistry Laboratory, Inc.
National Autonomous University of Mexico
National Cheng Kung University
National Institute for Health Research, United Kingdom
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute on Aging (NIA)
New York Presbyterian Hospital
Oregon Health and Science University
People's Liberation Army of China
Shin Kong Wu Ho-Su Memorial Hospital
Southeast Renal Research Institute
State University of New York, Brooklyn
State University of New York, Syracuse
The University of Texas, Dallas
Unidad de Investigacion Medica en Enfermedades Renales
Universidade Estadual de Londrina
Université catholique de Louvain
University of Campania Luigi Vanvitelli
University of Las Palmas de Gran Canaria
University of Naples Frederico II
University of Western Australia
Organization Involved with Phase 3 Indications (123)
Anandabawa Kidney Dialysis Center, Jamnagar
Apollo Hospitals, Chennai, India
Beijing Biostats Technology Co. Ltd.
Beijing Heyiyuan Biotech Co. Ltd.
Canadian Institutes of Health Research (CIHR)
Federal University of Rio Grande do Sul
General Hospital of Chinese Armed Police Forces
German Atrial Fibrillation Network
Guangdong Pharmaceutical University
Gujarat Kidney Foundation, Ahmedabad
Hamilton Health Sciences Corporation
Health Research Council, New Zealand
Henan Provincal People's Hospital
IKDRC, Civil Hospital, Ahmedabad
Institut National de la Santé Et de la Recherche Médicale, France
Instituto Nacional de Cardiologia Ignacio Chavez
Japan Blood Products Organization
LAL Clinical Reseach e Development Ltda
Muljibhai Patel Urological Hospital
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
Region Hospital Fredericia, Denmark
Sanjay Gandhi Postgraduate Institute of Medical Sciences
Sinomune Pharmaceutical Co., Ltd
State Department of Health of Rio Grande do Sul
Steno Diabetes Center Copenhagen
Translational Research Informatics Center, Kobe, Hyogo, Japan
Organization Involved with Phase 2 Indications (97)
Cooperative Clinical Trials in Pediatric Transplantation
D'Annunzio University of Chieti–Pescara
Guangdong Provincial Hospital of Traditional Chinese Medicine
Hospital Universitario Ramon y Cajal
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Katholieke Universiteit Leuven
National Center for Complementary and Integrative Health (NCCIH)
National Center for Research Resources (NCRR)
Orlando Clinical Research Center
PathWest Laboratory Medicine WA
Pirogov Russian National Research Medical University
Pulmonary and Critical Care Assoc. of Baltimore
Pulmonary Critical Care Associates of Baltimore
Russian Academy of Medical Sciences
Russian State Medical University
Organization Involved with Phase 1 Indications (35)
Organization Involved with Other Experimental Indications (60)
"Maggiore della Carità" Hospital
Medical University of South Carolina
National University of Malaysia
New Orleans Center for Clinical Research
The Physicians' Services Incorporated Foundation
Tung's Taiching MetroHarbor Hospital
Universidad Complutense de Madrid
University of Alabama, Birmingham
University of British Columbia
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
